ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO079

Renal Events Following Iodinated Contrast Aggravate Diabetic Nephropathy

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention


  • Fernandes, Sheila Marques, University of São Paulo, Carapicuíba, Brazil
  • Brandi, Beatriz De almeida, Universidade de São Paulo, São Paulo, Brazil
  • Peres, Karina Batista, EEUSP, São Paulo, Brazil
  • Santos, Luciana soares Costa, Universidade de São Paulo, São Paulo, Brazil
  • da Fonseca, Cassiane Dezoti, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
  • Watanabe, Miriam M., Faculdades Metrpolitana Unidas, São Paulo, Brazil
  • Vattimo, Maria De Fatima, Universidade de São Paulo, São Paulo, Brazil

Group or Team Name

  • Group of Studies on Acute Kidney Injury (GERA)

Iodinated contrast (IC) is a leading cause of AKI (CI-AKI) and occurs more frequently in individuals with increasingly common risk factors, including diabetes. IC-AKI has been growing in recent years faced with the more frequent diagnostic needs in old patients and with comorbid conditions such as diabetes. This complication is due to a number of factors, including the osmolality of the IC.
The aim of this study is to evaluate the injury in kidneys of diabetic rats submitted to treatment with high- osmolar and low-osmolar iodinated contrast, evaluating the impact on hemodynamic and renal function in addition to oxidative profile.


Wistar rats, male and adult, weighing 250-290g were randomized into four groups: Citrate, Diabetes Mellitus (DM), Diabetes+low-osmolar iodinated contrast (DM+LIC) and DM+high-osmolar iodinated contrast (DM+HIC). Physiological parameters (body weight, water and food intake, glycemia and kidney/body weight ratio); renal function (Inulin Clearance; urinary neutrophil gelatinase/uNGAL); hemodynamics (arterial blood pressure; renal blood flow/RBF; renal vascular resistance/RVR) and oxidative profile (urinary peroxides/UP, urinary TBARS, renal tissue thiols and urinary nitric oxide/NO) were evaluated.


Diabetic groups showed polyphagia, polydipsia, polyuria, high levels of blood glucose and reduction in body weight. DM group showed a reduced inulin clearance, elevated uNGAL, elevated RVR, reduced RBF, elevated UP, TBARS and NO and a consumption of antioxidant reserve. When IC was introduced, the parameters of renal function, renal hemodynamic and oxidative profile became worse, specially in the group DM+HIC.


The use of high and low osmolarity IC promoted additional deleterious action to renal function and hemodynamics with oxidative injury in diabetic rats, with a more expressive effect in the group submitted to high osmolality contrast treatment.

Renal function, hemodynamics, oxidative
Group (n)Serum creatinine (mg/min/kg)Inulin clearance (mL/min/kg)Neutrophil gelatinase-associated lipocalin (ng/mL)Renal blood flow (mL/min)Renal vascular resistance (mmHg/mL/min)Urinary peroxides (nmol/g creatinine)TBARS (nmol/g creatinine)Thiols (nmol/mg potein)Nitric oxide (µM/g creatinine)
Citrate (7)0.30±0,060.94±0.2341.41±4.638.19±0.7615.05±2.002.15±0.850.16±0.0430.92±7.4425.06±4.05
DM (7)0.80±0,25 *0.58±0.05 *57.25±14.443.96±0.70*26.34±5.60 *12.74±3.94 *1.09±0.28*15.75±1.17 *53.72±5.31 *
DM+LIC0.87±0,11 *#0.34±0.11 *#103.78±9.09 *#3.06±0.42 *#35.42±6.35 *#18.94±7.54 *#2.13±0.46 *#12.50±3.64 *#76.78±8.47 *#
DM+HIC1.47±0,66 *#&0.14±0.01 *#&167.27±8.50 *#&2.29±0.55 *#&44.97±6.06 *#&25.57±7.54 *#&3.31±0.47 *#&6.22±0.31 *#&88.23±8.47 *&

* p<0.05 versus Citrate; # p<0.05 versus DM; & p<0.05 versus DM+LIC


  • Government Support - Non-U.S.